Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2007-12-11
2007-12-11
Priebe, Scott D. (Department: 1633)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093100, C435S320100, C435S455000, C435S456000
Reexamination Certificate
active
11029942
ABSTRACT:
The invention provides a recombinant viral vector comprising the DNA of, or corresponding to, at least a portion of the genome of an adenovirus, which portion is capable of infecting a hepatic cell; and a human VLDL receptor gene operatively linked to regulatory sequences directing its expression. The vector is capable of expressing the normal VLDL receptor gene product in hepatic cells in vivo or in vitro. This viral vector is useful in the treatment of metabolic disorders caused by the accumulation of LDL in plasma, such as familial hypercholesterolemia or familial combined hyperlipidemia.
REFERENCES:
patent: 4658019 (1987-04-01), Kung
patent: 5017691 (1991-05-01), Lee
patent: 5139941 (1992-08-01), Muzyczka
patent: 5166320 (1992-11-01), Wu
patent: 5240846 (1993-08-01), Collins
patent: 5580776 (1996-12-01), Wilson
patent: 5652224 (1997-07-01), Wilson
patent: 5798209 (1998-08-01), Chan
patent: 5856152 (1999-01-01), Wilson
patent: 5872154 (1999-02-01), Wilson
patent: 6174527 (2001-01-01), Wilson
patent: 6316255 (2001-11-01), Mulligan
patent: 6887463 (2005-05-01), Wilson et al.
patent: 501233 (1992-09-01), None
patent: 555880 (1993-08-01), None
patent: WO90/05147 (1990-05-01), None
patent: WO91/18088 (1991-11-01), None
patent: WO93/00431 (1993-01-01), None
patent: WO94/10322 (1994-05-01), None
patent: WO94/12649 (1994-06-01), None
patent: WO94/17832 (1994-08-01), None
patent: WO 94/25073 (1994-11-01), None
patent: WO 95/02697 (1995-01-01), None
patent: WO95/06743 (1995-03-01), None
patent: WO95/13374 (1995-05-01), None
patent: WO97/32990 (1997-09-01), None
M. Boshart et al, “A Very Strong Enhancer is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus”, Cell, 41:521-530 (Jun. 1985).
M. Brown et al, “A Receptor-Mediated Pathway for Cholesterol Homeostasis”, Science, 232:34-47 (Apr. 4, 1986).
J. Cohen, “Naked DNA Points Way to Vaccines”, Science, 259:1691-1692 (Mar. 19, 1993).
K. Culver et al, “Gene Therapy for Cancer”, TIG, 10(5):174-178 (May 1994).
A. D'Andrea et al, “Production of Natural Killer Cell Stimulatory Factor (Interleukin 12) by Peripheral Blood Mononuclear Cells”, J. Exp. Med., 176:1387-1398 (Nov. 1992).
F. Durie et al, “The Role of CD40 in the Regulation of Humoral and Cell-Mediated Immunity”, Immunology Today, 15(9):406-411 (Sep. 1994).
J. Engelhardt et al, “Prolonged Transgene Expression in Cotton Rat Lung with Recombinant Adenoviruses Defective in E2a”, Human Gene Therapy, 5:1217-1229 (Oct. 1994).
J. Engelhardt et al, “Adenovirus-Mediated Transfer of the CFTR Gene to Lung of Nonhuman Primates: Biological Efficacy Study”, Human Gene Therapy, 4:759-769 (Dec. 1993).
J. Engelhardt et al, “Ablation of E2A in Recombinant Adenoviruses Improves Transgene Persistence and Decreases Inflammatory Response in Mouse Liver”, Proc. Natl. Acad. Sci. USA, 91:6196-6200 (Jun. 1994).
K. Fisher et al, “Biochemical and Functional Analysis of an Adenovirus-Based Ligand Complex for Gene Transfer”, Biochem. J., 299:49-58 (Apr. 1, 1994).
P. Frykman et al, “Normal Plasma Lipoproteins and Fertility in Gene-Targeted Mice Homozygous for a Disruption in the Gene Encoding Very Low Density Lipoprotein Receptor”, Proc. Natl. Acad. Sci. USA, 92:8453-8457 (Aug. 1995).
M. Gafvels et al, “Cloning of a cDNA Encoding a Putative Human Very Low Density Lipoprotein/Apolipoprotein E Receptor and Assignment of the Gene to Chromosome 9pter-p23”, Somatic Cell and Molecular Genetics, 19(6):557-569 (Sep. 1993).
M. Gafvels et al, “Cloning of a Complementary Deoxyribonucleic Acid Encoding the Murine Homolog of the Very Low Density Lipoprotein/Apolipoprotein-E Receptor: Expression Pattern and Assignment of the Gene to Mouse Chromosome 19”, Endocrinology, 135(1):387-394 (Jul. 1994).
J. Goldstein et al, “Familial Hypercholesterolemia”, in The Metabolic Basis of Inherited Disease, Chapter 48, 6thed., C.R. Scrivers et al (eds), McGraw-Hill Information Services Co., New York, pp. 1215-1250 (1989).
J. Goldstein et al, “Defective Lipoprotein Receptors and Atherosclerosis—Lessons from an Animal Counterpart of Familial Hypercholesterolemia”, New Engl. J. Med., 309(5):288-296 (Aug. 4, 1983).
J. Goldstein et al, “Disorders of the Biogenesis and Secretion of Lipoproteins”, in The Metabolic Basis of Inherited Disease, Chapter 44B, 6thed., C.R. Scrivers et al (eds), McGraw-Hill Information Services Co., New York, pp. 1155-1156 (1989).
M. Grable et al, “cis and trans Requirements for the Selective Packaging of Adenovirus Type 5 DNA”, J. Virol., 66(2):723-731 (Feb. 1992).
M. Grable et al, “Adenovirus Type 5 Packaging Domain is Composed of a Repeated Element that is Functionally Redundant”, J. Virol., 64(5):2047-2056 (May 1990).
M. Grossman et al, “Towards Liver-Directed Gene Therapy: Retrovirus-Mediated Gene Transfer into Human Hepatocytes”, Somatic Cell and Molecular Genetics, 17(6):601-607 (Nov. 1991).
P. Hearing et al, “Identification of a Repeated Sequence Element Required for Efficient Encapsidation of the Adenovirus Type 5 Chromosome”, J. Virol., 61(8):2555-2558 (Aug. 1987).
F. Heinzel et al, “Recombinant Interleukin 12 Cures Mice Infected with Leishmania major”, J. Exp. Med., 177:1505-1509 (May 1993).
C. Hodgson, “Advances in Vector Systems for Gene Therapy”, Exp. Opin. Ther. Patents, 5(5):459-468 (1995).
M. Horwitz, Adenoviridae and Their Replication, Virology, 2ndedition, ed. B. N. Fields, Raven Press, Ltd., New York, Chapter 60, pp. 1679-1721 (1990).
S. Ishibashi et al, “Hypercholesterolemia in Low Density Lipoprotein Receptor Knockout Mice and its Reversal by Adenovirus-mediated Gene Delivery”, J. Clin. Invest., 92:883-893 (Aug. 1993).
S. Ishibashi et al, “Massive Xanthomatosis and Atherosclerosis in Cholesterol-fed Low Density Lipoprotein Receptor-negative Mice”, J. Clin. Invest., 93:1885-1893 (May 1994).
T. Kost et al, “The Nucleotide Sequence of the Chick Cytoplasmic beta-actin gene”, Nucleic Acids Research, 11(23):8287-8301 (Dec. 11, 1983).
K. Kozarsky et al, “Effective Treatment of Familial Hypercholesterolaemia in the Mouse Model Using Adenovirus-mediated Transfer of the VLDL Receptor Gene”, Nature Genetics, 13:54-62 (May 1996).
K. Kozarsky et al, “In Vivo Correction of Low Density Lipoprotein Receptor Deficiency in the Watanabe Heritable Hyperlipidemic Rabbit with Recombinant Adenoviruses”, J. Biol. Chem., 269(18):13695-13702 (May 6, 1994).
K. Kozarsky et al, “Gene Therapy: Adenovirus Vectors”, Current Opinion in Genetics and Development, 3:499-503 (Mar. 1993).
K. Kozarsky et al, “Adenovirus-Mediated Correction of the Genetic Defect in Hepatocytes from Patients with Familial Hypercholesterolemia”, Somatic Cell and Molecular Genetics, 19(5):449-458 (Sep. 1993).
C. Laughlin et al, “Cloning of Infectious Adeno-Associated Virus Genomes in Bacterial Plasmids”, Gene, 23:65-73 (Jul. 1983).
M. Levrero et al, “Defective and Nondefective Adenovirus Vectors for Expressing Foreign Genes in vitro and in vivo”, Genes, 101:195-202 (1991).
J. Logan et al, “Adenovirus Tripartite Leader Sequence Enhances Translation of mRNAs Late After Infection”, Proc. Natl. Acad. Sci. USA, 81:3655-3659 (Jun. 1984).
R. Manetti et al, “Natural Killer Cell Stimulatory Factor *Interleukin 12 [IL-12]) Induces T Helper Type 1 (Th1)-Specific Immune Responses and Inhibits the Development of IL-4-producing Th Cells”, J. Exp. Med., 177:1199-1204 (Apr. 1993).
E. Marshall et al, “Gene Therapy's Growing Pains”, Science, 269:1050-1055 (Aug. 25, 1995).
N. Miller et al, “Targeted Vectors for Gene Therapy”, FASEB J., 9:190-199 (1995).
S. Morris et al, “Effects of IL-12 on in Vivo Cytokine Gene Expression and Ig Isotype Selection”, J. Immunol.,
Kozarsky Karen
Strauss, III Jerome
Wilson James M.
Howson & Howson LLP
Priebe Scott D.
The Trustees of the University of Pennsylvania
LandOfFree
Methods and compositions for the treatment of defects in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for the treatment of defects in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for the treatment of defects in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3869682